Our latest research, company updates and industry insight
PD-Monitor could differentiate Parkinson’s from essential tremor without bradykinesia with high accuracy, sensitivity and specificity – according to a study.
Professor Smith highlighted the work of ClearSky in diagnosing and monitoring Parkinson’s at a UK–China university consortium in November.
ClearSky’s PD-Monitor has been used in a nationwide study to investigate whether statins are effective in slowing the progress of Parkinson’s.
ClearSky Medical Diagnostics is recognised as an ‘up and coming’ company tackling neurodegenerative disease through technology.
ClearSky has launched a new study in China to establish introducing bradykinesia as a feature being measured by LID-Monitor.
ClearSky’s Professor Stephen Smith hosted a stand at an innovation exchange event in Leeds in January – part of a prestigious international innovation programme that the city of Leeds was chosen to host with Massachusetts Institute of Technology (MIT).
John has Parkinson’s – in this blog he explains how using the LID-Monitor could help with managing when patients take their Levodopa medication.
ClearSky Medical Diagnostics is thrilled to announce that two LID-Monitors, designed to help people with Parkinson’s control their condition, have been acquired at a hospital in Leeds.
Experimental work being undertaken in the development of ClearSky’s CF-Monitor will be presented at the MedGEC Workshop at GECCO 2019 in Prague in July.
ClearSky will showcase its technology and products at an international summit of medical innovators at Nanjing Tech Week in China this week.
ClearSky Medical Diagnostics has forged a partnership with Shimmer Research – a leading provider of wearable wireless sensing solutions – to bring a new level of analytic capabilities to the use of wearable sensors in clinical research.
The ClearSky Medical Diagnostics team will be attending the 23rd International Congress of Parkinson’s Disease and Movement Disorders (MDS) in September 2019.